Trial Profile
A double-blind, randomised, dose ranging, multi-centre, phase IIIb study to evaluate the efficacy and safety of high doses of candesartan cilexetil (Atacand) on the reduction of proteinuria in the treatment of subjects with hypertension and moderate to severe proteinuria
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2008
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Hypertension
- Focus Pharmacodynamics
- 17 Dec 2007 Status changed from in progress to completed.
- 10 Jan 2007 Status change
- 14 Nov 2005 New trial record.